Neurosurgeons at Allegheny Health Network Spine Center in Pittsburgh have implemented SI-Bone's iFuse Implant System to treat sacroiliac joint dysfunction.
Four notes:
1. Sacroiliac joint dysfunction, also known as sacroiliitis, is an inflammation of one or both of the sacroiliac joints. The condition is responsible for an estimated 15 to 30 percent of all chronic lower back pain.
2. Sacroiliitis is more often seen in women and can be caused by pregnancy and small repetitive injuries that occur over time, including sports-related and traumatic injuries, Allegheny Health Network said in a Jan. 27 news release.
3. IFuse, developed by sacropelvic company SI-Bone, has been evaluated in 90 peer-reviewed publications and has become the standard of care for sacroiliac joint fusion, according to the company. Clinical trial results of its iFuse-3D implant system demonstrated significant improvements in sacroiliac joint pain, function and quality of life at 24 months, as well as a notable reduction in opioid use for patients with sacroiliac joint pain.
4. "IFuse is the only technology of its kind for treating sacroiliac joint dysfunction that is supported by level-1 evidence, which is the gold-standard clinical research benchmark for demonstrating medical efficacy," said Nestor Tomycz, MD, a neurosurgeon at Allegheny Health Network.